C

CARNIO S.

Last name: CARNIO S.

2022 (v1)

Publication

Metadata-only

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Tagliamento M. Bironzo P. Curcio H.

Introduction: Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) in pre-treated asMM. Methods: A systematic review of the literature of clinical trials testing single-agent anti...

Uploaded on: February 11, 2024
2020 (v1)

Publication

Metadata-only

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Cortellini A. Tiseo M. Banna G. L.

Background: Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%. Methods: We conducted a multicenter retrospective study aimed at evaluating the clinicopathologic correlates of pembrolizumab effectiveness in...

Uploaded on: April 14, 2023